Ieq Capital, LLC Neurocrine Biosciences Inc Transaction History

Ieq Capital, LLC

$32.2 Billion
Q3 2025

A detailed history of Ieq Capital, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ieq Capital, LLC holds 692,601 shares of NBIX stock, worth $100 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares

692,601

Previous 572,973 20.88%

Holding current value

$100 Million

Previous $72 Million 35.01%

% of portfolio

0.3%

Previous 0.45%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$123.98 - $146.67 $14.8 Million - $17.5 Million	119,628 Added 20.88%	692,601 $97.2 Million
Q2 2025 Aug 14, 2025	BUY	$87.54 - $128.18 $3.15 Million - $4.61 Million	35,956 Added 6.7%	572,973 $72 Million
Q1 2025 May 14, 2025	SELL	$107.22 - $153.29 $2.24 Million - $3.2 Million	-20,887 Reduced 3.74%	537,017 $59.4 Million
Q4 2024 Jan 31, 2025	BUY	$111.62 - $139.44 $5.07 Million - $6.33 Million	45,424 Added 8.86%	557,904 $76.2 Million
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $732,624 - $979,241	6,394 Added 1.26%	512,480 $59 Million

Q2 2024 Aug 12, 2024	SELL	$130.86 - $143.19 $3,533 - $3,866	-27 Reduced 0.01%	506,086 $69.7 Million
Q1 2024 May 08, 2024	BUY	$130.4 - $143.74 $3.04 Million - $3.35 Million	23,287 Added 4.82%	506,113 $69.8 Million
Q4 2023 Feb 07, 2024	BUY	$106.07 - $132.76 $162,074 - $202,857	1,528 Added 0.32%	482,826 $63.6 Million
Q3 2023 Nov 03, 2023	BUY	$94.02 - $117.1 $2,820 - $3,513	30 Added 0.01%	481,298 $54.1 Million
Q2 2023 Aug 07, 2023	BUY	$89.53 - $104.87 $43.1 Million - $50.5 Million	481,268 New	481,268 $45.4 Million

Others Institutions Holding NBIX

# of Institutions

724

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ieq Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ieq Capital, LLC with notifications on news.

Account